68Ga-TP1580 as a novel molecular probe for HER2-positive tumor imaging using MicroPET

被引:0
|
作者
Zhong, Jinxiu [1 ]
Pan, Donghui [2 ]
Guan, Yan-xing [3 ]
机构
[1] Nanchang Univ, Jiangxi Canc Hosp, Nanchang 330006, Jiangxi, Peoples R China
[2] Jiangsu Inst Nucl Med, Key Lab Nucl Med, Wuxi 210463, Jiangsu, Peoples R China
[3] Nanchang Univ, Affiliated Hosp 1, Dept Nucl Med Radiol, Nanchang 330006, Jiangxi, Peoples R China
关键词
HER2; MicroPET; Imaging; Peptides; BREAST-CANCER; CLINICAL-APPLICATIONS; HER2; EXPRESSION; PET; RECEPTOR; ANTAGONISTS; PEPTIDES; TOMOGRAPHY; CARCINOMAS; THERAPY;
D O I
10.1007/s10967-022-08236-x
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
HER2 is an attractive target for the treatment of breast cancer. Tc-99(m)-labeled HER2-specific binding to the small molecule mimetic peptide B2-S22-AFA shows the potential of detecting HER2 expression in vivo (Zhang in Transl Oncol 10:518-526, 2017). However, the low resolution of SPECT-CT imaging and the inability to quantitatively analyze may partially limit its wide use.Ga-68 is an excellent PET radionuclide due to availability, nearly quantitative reaction, and short physical half-life. In this study, Ga-68-labeled-NOTA- B2-S22-AFA (hereinafter referred to as Ga-68-TP1580) was applied for PET-CT imaging in HER2 breast cancer xenografts mice. In vitro studies and MicroPET imaging were performed in the SKBR-3 breast cancer model. Ga-68-TP1580 could be produced within 20 min with 93.2 +/- 2.1% yield and the radiochemical purity was greater than 95%. The tracer was stable in PBS and human serum for at least 2 h. MicroPET imaging revealed that the SKBR-3 xenografts were visualized and the tumor uptakes were 1.22 +/- 0.04, 0.71 +/- 0.07, and 0.43 +/- 0.04% ID/g at 0.5 h, 1 h, and 2 h.The corresponding tumor-to-blood and tumor-to-muscle ratios were 1.05 +/- 0.06, 1.34 +/- 0.21, and 1.33 +/- 0.57, respectively, and 4.02 +/- 1.39, 7.47 +/- 2.86, and 5.82 +/- 1.98 at 0.5 h, 1 h, and 2 h. No significant decrease in tumor uptake of Ga-68-TP1580 was seen after injection of excess unlabeled TP1580.In conclusion, TP1580 can be labeled by Ga-68 with high radiochemical purity (> 95%), good vitro stability (keep consistent radiochemical purity > 95% for more than 2 h).Ga-68-TP1580 can combine with target tissue and show some tumor uptake in SKBR-3 xenografts, but not be blocked by NOTA-B2-S22-AFA which indicates poor specificity.
引用
收藏
页码:1531 / 1543
页数:13
相关论文
共 50 条
  • [31] A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)
    Wege, Anja Kathrin
    Kirchhammer, Nicole
    Kazandjian, Linda Veronique
    Prassl, Sandra
    Brandt, Michael
    Piendl, Gerhard
    Ortmann, Olaf
    Fischer, Stephan
    Brockhoff, Gero
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [32] A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
    Shengnan Yu
    Jing Zhang
    Yongxiang Yan
    Xudong Yao
    Lijuan Fang
    Hui Xiong
    Yang Liu
    Qian Chu
    Pengfei Zhou
    Kongming Wu
    Journal of Experimental & Clinical Cancer Research, 38
  • [33] Smart Bacterial Magnetic Nanoparticles for Tumor-Targeting Magnetic Resonance Imaging of HER2-Positive Breast Cancers
    Zhang, Yunlei
    Ni, Qianqian
    Xu, Chaoli
    Wan, Bing
    Geng, Yuanyuan
    Zheng, Gang
    Yang, Zhenlu
    Tao, Jun
    Zhao, Ying
    Wen, Jun
    Zhang, Junjie
    Wang, Shouju
    Tang, Yuxia
    Li, Yanjun
    Zhang, Qirui
    Liu, Li
    Teng, Zhaogang
    Lu, Guangming
    ACS APPLIED MATERIALS & INTERFACES, 2019, 11 (04) : 3654 - 3665
  • [34] Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
    Liu, Li
    Greger, James
    Shi, Hong
    Liu, Yuan
    Greshock, Joel
    Annan, Roland
    Halsey, Wendy
    Sathe, Ganesh M.
    Martin, Anne-Marie
    Gilmer, Tona M.
    CANCER RESEARCH, 2009, 69 (17) : 6871 - 6878
  • [35] Novel EXO-T vaccine using polyclonal CD4+ T cells armed with HER2-specific exosomes for HER2-positive breast cancer
    Li, Rong
    Chibbar, Rajni
    Xiang, Jim
    ONCOTARGETS AND THERAPY, 2018, 11 : 7089 - 7093
  • [36] 68Ga-ZHER2 PET/CT Reveals HER2-Positive Metastatic Gastric Cancer With Better Image Quality Than 18F-FDG
    Zhou, Nina
    Guo, Xiaoyi
    Yang, Min
    Zhu, Hua
    Yang, Zhi
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (02) : E101 - E102
  • [37] Comparison of an Affibody-based Molecular Probe and 18F-FDG for Detecting HER2-Positive Breast Cancer at PET/CT
    Guo, Xiaoyi
    Zhou, Nina
    Liu, Jiayue
    Ding, Jin
    Liu, Teti
    Song, Guohong
    Zhu, Hua
    Yang, Zhi
    RADIOLOGY, 2024, 311 (03)
  • [38] Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68Ga
    Lindbo, Sarah
    Garousi, Javad
    Mitran, Bogdan
    Vorobyeva, Anzhelika
    Oroujeni, Maryam
    Orlova, Anna
    Hober, Sophia
    Tolmachev, Vladimir
    MOLECULAR PHARMACEUTICS, 2018, 15 (07) : 2674 - 2683
  • [39] Targeting HER2-positive gastric cancer with a novel 18F-labeled ZHER2:342 probe
    Pan, Yunyun
    Yang, Zhengyang
    Xu, Yuping
    Bai, Zhicheng
    Pan, Donghui
    Yang, Runlin
    Wang, Lizhen
    Guan, Wenxian
    Yang, Min
    RSC ADVANCES, 2019, 9 (19): : 10990 - 10998
  • [40] Radiosynthesis and preclinical evaluations of [18F]AlF-RESCA-5F7 as a novel molecular probe for HER2 tumor imaging
    Tian, Ruhua
    Kong, Jinping
    He, Yingfang
    Xu, Guoqiang
    Chen, Tengxiang
    Han, Junbin
    AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 14 (03): : 175 - 181